C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNYSE:BCR
CUSIP06738310
Phone+1-908-2778000
Debt
Debt-to-Equity Ratio0.57
Current Ratio1.72
Quick Ratio1.37
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio27.86
P/E Growth2.53
Sales & Book Value
Annual Sales$3.71 billion
Price / Sales6.50
Cash Flow$13.4760 per share
Price / Cash24.58
Book Value$22.78 per share
Price / Book14.54
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$531.40 million
Net Margins9.51%
Return on Equity19.39%
Return on Assets6.91%
Miscellaneous
Employees16,300
Outstanding Shares72,890,000
Market Cap$24.14 billion
C R Bard (NYSE:BCR) Frequently Asked Questions
What is C R Bard's stock symbol?
C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."
How were C R Bard's earnings last quarter?
C R Bard Inc (NYSE:BCR) issued its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the consensus estimate of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The company's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.64 earnings per share. View C R Bard's Earnings History.
What price target have analysts set for BCR?
3 equities research analysts have issued 12-month price objectives for C R Bard's stock. Their forecasts range from $317.00 to $337.00. On average, they expect C R Bard's share price to reach $327.00 in the next year. This suggests that the stock has a possible downside of 1.3%. View Analyst Price Targets for C R Bard.
What is the consensus analysts' recommendation for C R Bard?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for C R Bard in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for C R Bard.
What are Wall Street analysts saying about C R Bard stock?
Here are some recent quotes from research analysts about C R Bard stock:
- 1. According to Zacks Investment Research, "In the last year, C. R. Bard has outperformed the broader industry trends with respect to price performance. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth. " (12/26/2017)
- 2. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017)
Who are C R Bard's key executives?
C R Bard's management team includes the folowing people:
- Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
- John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
- James C. Beasley, Group President (Age 53)
- Timothy P. Collins, Group President (Age 56)
- John P. Groetelaars, Group President (Age 50)
- Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
- Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
- John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
- Frank Lupisella Jr., Vice President, Controller (Age 56)
- Betty D. Larson, Vice President - Human Resources (Age 41)
How do I buy shares of C R Bard?
Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is C R Bard's stock price today?
One share of BCR stock can currently be purchased for approximately $331.24.
How big of a company is C R Bard?
C R Bard has a market capitalization of $24.14 billion and generates $3.71 billion in revenue each year. C R Bard employs 16,300 workers across the globe.
What is C R Bard's official website?
How can I contact C R Bard?
C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.
MarketBeat Community Rating for C R Bard (NYSE BCR)
MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
